From the June 2013 revision to the SNTA website's corporate presentation...
This portion of the presentation appears to have been added recently.
Interesting that it's appearance is coincidental to recent insider buying.
A PR might provide some entertaining catalyst...
A copy and paste won't work. The presentation is a graph with a biblioraphical reference to three research papers, which I took some time to review today. I can't find verification that any preclinical work has taken place wrt ganetespib and PD-1 inhibition. The rationale for such a work-up has been suggested, but to my knowledge, not actually initiated. Check out: "Combination therapy with HSP90i 17-DMAG reconditions the tumor micro environment to improve recruitment of therapeutic T cells"
I also cruised the clinicltrialsdotgov site, checking all the advanced PD-1 inhibitor sites for early trial work-ups. I could find nothing w/ Nivolumab, lambrolizumb, MPDL-3280A, or CT-011. To my knowledge, there are no other PD-1 inhibitors that might qualify. I think SNTA has some explaining to do wrt the presentation. If any preclinical work has been done w ganetespib and PD-1 inhibition, that work has yet to be presented and published. JMHO - but I figure we are awaiting a news release to explain the omission.